Statement of Translational Relevance. We demonstrate here that small interference RNAbased silencing of the survivin splice variant 2B inhibits cell growth in vitro and reduces tumor growth in orthotopic models of taxane-resistant ovarian cancer. Furthermore, we found a significant association between survivin 2B expression and progression free survival in epithelial ovarian cancers obtained at primary debulking surgery. These data identify survivin 2B as an important target in ovarian cancer, and provide a translational path forward for developing new therapies against this target.
Introduction
Survivin [baculoviral IAP repeat-containing protein (BIRC-5)] belongs to the inhibitor of apoptosis protein (IAP) family (1, 2) characterized by one to three BIR (Baculoviral IAP repeats) domains, a COOH-terminal RING finger domain, and a caspase recruitment domain (2) . However, in contrast with other IAPs, survivin lacks a RING finger domain (2) . The mechanisms by which survivin, and other IAPs, exert their anti-apoptotic effect have been well characterized in vitro and in vivo (3) (4) (5) .
This mechanism involves formation of a complex between IAPs and effector caspases (2, 6 ) that result in inhibition of the apoptotic pathway (6) . As a subunit of the chromosomal passenger complex (CPC), survivin also plays a critical role in the regulation of mitosis (7, 8) .
Survivin has been amply considered an anticancer target because it is highly expressed in several types of cancer, but is largely undetectable in most normal adult tissues (1, 9) . Evidence also indicates that survivin plays a central role in cancer drug resistance (10) (11) (12) (13) . In ovarian cancer, progressive taxane resistance in vitro is associated with increasing survivin expression (11) . Likewise, higher levels of survivin have been observed in advanced ovarian carcinomas associated with clinical resistance to a paclitaxel/platinum chemotherapy compared with drug sensitive-cases (11) .
Five different isoforms of survivin, arising from alternative splicing of the survivin (BIRC-5) gene, have been identified (14) (15) (16) (17) . These include the wild-type (WT) survivin, survivin 2B, survivin 3B, survivin ΔEx3 and survivin 2α (14, 15, 17, 18) . Growing evidence indicates that the survivin splice variants could have different, even opposite, biological roles (16, 17, 19, 20) . While some survivin splice variants could play an anti-apoptotic role, others could be associated with mitosis (14-16, 21, 22) . The lack of information regarding the biological role of survivin splice variants in taxaneresistant ovarian cancer prompted us to consider their specific roles. Our data indicate that compared with taxane-sensitive counterparts, taxane-resistant ovarian cancer cells express higher mRNA levels of specific survivin splice variants, particularly survivin 2B. Here, we examined the In vitro and in vivo effects of silencing of survivin splice variants in pre-clinical models of ovarian cancer, and determined the clinical significance of survivin 2B mRNA expression levels in ovarian cancers.
Materials and Methods

Cells and culture conditions
The human ovarian epithelial cancer cells SKOV3ip1, SKOV3.TR, HeyA8, HEYA8.MDR, A2780PAR and A2780CP20 cells have been described elsewhere (23) (24) (25) (26) . All tumor cell lines were screened for Mycoplasma using MycoAlert (Cambrex Bioscience) as described by the manufacturer. Cells were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) in 5% CO 2 /95% air at 37°C. In vitro assays were performed at 70-85% cell density.
Chemicals, reagents and antibodies
For in vitro testing, docetaxel and paclitaxel were reconstituted in 100% DMSO. When added to the cells, the final concentration of DMSO on the culture medium was 0.1% or less. Monoclonal Sigma-Aldrich (St. Louis, MO). Mouse and rabbit horseradish peroxidase-conjugated secondary antibodies were purchased from Sigma-Aldrich.
Western blot analysis
Cells were washed with cold PBS, lysed with ice-cold lysis buffer and incubated on ice for 30 min.
Lysates were centrifuged, supernatants were collected, and protein concentration was determined using Bio-Rad Protein Reagents (Bio-Rad, Hercules, CA). Protein lysates (30 μg) were separated by SDS-PAGE, blotted onto membranes, and probed with the appropriate dilution of each primary antibody. Membranes were rinsed and incubated with the appropriate horseradish peroxidase-conjugated secondary antibody, rinsed again, and the bound antibodies were detected using enhanced chemiluminescence (GE Healthcare, Piscataway, NJ) following by autoradiography in a FluorChem TM 8900 (Alpha Innotech Corporation, San Leandro, CA).
RNA isolation and SYBR-1-based real-time polymerase chain reaction (PCR)
Total RNA was extracted from cells using the Rneasy kit from Qiagen (Valencia, CA). Total RNA (1.0 μg) was subjected to reverse transcription in a reaction mix containing 500 mg/ml oligo dT, 1X First Strand Buffer, 0.01 M DTT, 0.5 mM dNTP mix, and 200 units of MMLV RT (Invitrogen, Carlsbad, CA) to a final volume of 20 ml, and incubated at 40°C for 2 hr. The resulting first-strand cDNA was used as a template for SYBR-I-based real-time PCR analysis (27 Small interfering RNA (siRNA) and in vitro siRNA transfection
To silence total human survivin (NM_001168), siRNA (5'-CAGACTTGGCCCAGTGTTT-3') was designed in exon 2, which is common to all survivin splice variants. SiRNA duplex targeting the 5'-AATACCAGCACTTTGGGAG-3' sequence in the open reading frame of the human survivin-2B
(NM_001012271) and a non-silencing negative control siRNA (C-siRNA) was used. SiRNAs were purchased from Sigma. Briefly, 3x10 4 cells/ml were plated in 6-well plates. Twenty-four hours 
In vitro cell viability assay
SiRNA incorporation into DOPC nanoliposomes
For in vivo delivery, siRNAs were incorporated into 1,2-Dioleoyl-sn-Glycero-3-Phosphocholine presence of excess t-butanol at a ratio of 1:10 (w/w) as described previously (23, 24, (30) (31) (32) To evaluate the therapeutic activity of survivin siRNAs alone or in combination with docetaxel HeyA8.MDR were injected i.p. Seven days later, the mice (N=10 per group) were randomly assigned to seven treatment groups (all treatments were administered i.p.): 1) C-siRNA, 2) docetaxel (DTX) alone, 3) C-siRNA-plus DTX, 4) T-siRNA, 5) T-siRNA plus DTX, 6) 2B-siRNA, and 7) 2B-siRNA plus DTX. Liposomal-siRNAs (5 μg siRNA/injection) were injected twice a week and docetaxel (50 µg/injection) once a week (23, 24) . The therapeutic experiment was repeated with SKOV3.TR cells.
Immunohistochemistry
Expression of Ki67 (cell proliferation marker) and Immunohistochemistry for CD31 (microvessel density) were done on paraffin-embedded tumors as described before (23, 24, 30) . Ki67 primary antibody (BioCare Medical, Concord, CA) and secondary goat HRP anti-rabbit (Jackson Laboratories, Bar Harbor, ME) were used. The primary antibody used for CD31 was an anti-CD31
(platelet/endothelial cell adhesion molecule-1, rat IgG; BD Pharmingen, San Diego, CA).
Secondary antibody was goat HRP anti-rat (Jackson Laboratories, Bar Harbor, ME). Assessment
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of deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)-positive cells (apoptosis) were determined by immunohistochemical analysis using freshly cut frozen tissue as described previously (23, 24, 30, 31) .
To quantify microvessel density (MVD), 10 random fields at 100x final magnification were examined for each tumor (one slide per mouse, five slides per group) and the number of microvessels per field was counted (23, 24, 26) . To quantify Ki67 expression, the number of positive and negative cells (3,3'-diaminobenzidine staining) was counted in 10 random fields at 100x magnification and the percent of Ki67 positive cells was calculated for each group (23, 24, 26) . To quantify TUNEL positive cells, the number of positive cells was counted in 10 random fields at 100x magnification (23, 24, 26) .
RNA extraction from human epithelial ovarian cancer specimens
After obtaining Institutional Review Board approval, we obtained 117 human epithelial ovarian carcinoma specimens that were archived and freshly frozen at the time of primary debulking at the University of Texas M.D. Anderson Cancer. These samples (35 mg, each) were frozen in liquid nitrogen and homogenized with trizol (1 µL; Invitrogen) using mortar and pestle. Chloroform (200 µL) was added and samples were centrifuged at 12000 x g. Total RNA was precipitated with isopropanol (500 µL), washed with 75% ethanol, air-dried, and dissolved in RNase-free water.
RNA quality and concentration was determined and RNA with > 1.5 OD ratio (260/280) was utilized to generate complementary DNA (cDNA) using superscript-II reverse transcriptase kit (Invitrogen) as previously described (27, 29) . Kaplan-Meier survival curves were used to determine the association between the survivin 2B mRNA expression levels and survival endpoints (both progression-free (PFS) and overall survival (OS) times, both measured from the time of debulking surgery).
Statistical analysis
For in vivo experiments, differences in continuous variables (mean body weight, tumor weight, MVD, Ki-67 and TUNEL staining) were analyzed using the Student's t test for comparing two groups and by ANOVA for multiple group comparisons with P < 0.05 considered statistically significant. To examine the interaction index (II) between T-siRNA, 2B-siRNA and docetaxel, an isobolanalysis was used as described by Feleszko et al (33) . Briefly, equieffective concentrations (concentrations of either drug, alone, or in combination that gave equivalent inhibition of cell growth as compared with untreated control cells) were calculated. The interaction index for combination of the two drugs was calculated according to the following equation:
where siRNAa and DTXa are concentrations of T-siRNA, 2B-siRNA and docetaxel, respectively, that produce some specified effect when used alone, and siRNAc and c are concentrations of TsiRNA, 2B-siRNA and docetaxel, respectively, that produce the same effect when used in combination. The interaction is considered synergistic when the II is less than 1.0.
Results
Expression of survivin splice variants in ovarian cancer cells.
We first performed growth inhibition experiments to confirm the responsiveness of the ovarian parental cancer cells lines HEYA8 and SKOV3ip1, and their taxane resistant counterparts, HEYA8.MDR and SKOV3i.TR, respectively (31-33) ( Figure 1S ). As expected, the resistant cells had no response while the sensitive cells had a dose-dependent response.
We next used SYBR-I-real time PCR to compare the mRNA expression levels of the five survivin splice variants in taxane-sensitive ovarian cancer cells and their taxane-resistant counterparts cancer cell and its cisplatin resistant counterpart, AP2780CP20. The mRNA expression levels of survivin 2α and survivin 3B were negligible as compared to other isoforms. Therefore, we focused on the survivin 2B isoform for all subsequent work.
Effects of survivin 2B silencing on cell growth
SiRNAs were designed around exon two ( Figure 2S-A) to silence all splice variants (T-siRNA).
Another set of siRNAs were designed to specifically silence survivin 2B ( Figure 2S-A) . We next studied the biological effects of siRNA-based silencing of survivin 2B (2B-siRNA) as compared to silencing total Survivin (Figure 2A ). Real-time PCR experiments demonstrated that T-siRNA significantly reduced the levels of total survivin and the survivin splice variants WT, 2B and ΔEX3 in the HeyA8-MDR cell line. 2B-siRNA inhibited the expression of this isoform, but not survivin WT or ΔEX3, demonstrating that this siRNA was specific for survivin 2B. Maximal silencing of both survivin 2B and total survivin was observed at 24-hr ( Figure 2S-B) . Dose-dependent growth inhibition was observed after 72-hr incubation of HEYA8.MDR cells with the T-survivin-siRNA or 2B-siRNA ( Figure 2B ). We also studied the effects of combining nonactive doses of T-siRNA or 2B-siRNA with non-active doses of docetaxel ( Figure 2C ). Significant reduction in growth inhibition was observed with these combinations, synergism was observed at all concentrations tested ( Figure 3S-A-B) . Combination of an inactive dose of siRNA (25 nM), with different docetaxel concentrations induced additive growth inhibitory effects, even at 10 nM docetaxel ( Figure 3S-C) . Cell growth inhibition was also observed after transfection of HEYA8.MDR cells with other different siRNAs against total survivin and survivin 2B ( Figure 4S ).
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These results indicate that the growth inhibitory effects observed were indeed due to survivinsilencing.
Effects of survivin-2B silencing on apoptosis and cell cycle progression
We next investigated whether the growth inhibition induced by T-siRNA or 2B-siRNA was due to apoptosis ( Figure 3A) . Transfection of HEYA8.MDR cells with T-siRNA induced up to 35% apoptosis while 2B-survivin silencing induced up to 15% apoptosis *p<0.01). These results were confirmed by Western blot analysis, which showed that silencing survivin 2B induced lower levels of PARP-1 cleavage and lower activation of caspase-9 and caspase-3 ( Figure 3B ) when compared with cells incubated with T-siRNA. No difference was observed in the cleavage product of caspase-8, between T-siRNA and 2B-siRNA. These latter effects were expected as caspase-8 is upstream of survivin in the apoptotic pathway (1, 2).
Survivin and its splice variants are known to play a central role during mitosis (1, 15, 34) , thus, we also assessed whether cell cycle arrest is induced by survivin-2B silencing ( Figure 3C ). More than 80% of the HEYA8.MDR cells were arrested in G1 phase after 48-hr of transfection with 2B-siRNA ( Figure 3C ). Western blot analysis confirmed that key proteins required for transition from G1 to S phase (35-37) were downregulated Cyclin-E (40%) and cdk2 (80%)], while p27 which blocks cyclin E and cdk2 function (35) was upregulated (50%), in 2B-siRNA transfected cells ( Figure 3D-E) .
Therapeutic effect of 2B-siRNA-DOPC
DOPC-based nanoliposomes were used for the animal models as previously described (23, 24, Research. (23, 24) . All siRNA-DOPC treatments were given twice a week for 6 weeks. DTX by itself did not induce a significant effect on tumor growth ( Figure 4A ). Decreased tumor weight was observed in both T-siRNA-DOPC and 2B-siRNA-DOPC groups (*p< 0.05 for both, T-siRNA-DOPC, and 2B-siRNA-DOPC). Tumor weight was further reduced when DTX was added to T-siRNA-DOPC and 2B-siRNA-DOPC (**p<0.01 for both, T-siRNA-DOPC plus DTX, and 2B-siRNA-DOPC plus DTX).
Similar results were obtained with treatment of SKOV3.TR-bearing mice with T-siRNA-DOPC and 2B-siRNA-DOPC alone or in combination with DTX ( Figure 4C ). T-siRNA-DOPC or 2B-siRNA-DOPC induced a significant decrease in the number of tumor nodules in both, HEYA8.MDR tumor bearing mice (**p< 0.01, Fig. 4B ), and SKOV3.TR (**p < 0.01, Figure 4D ). No further reduction in the number of tumor nodules was observed when DTX was combined with either TsiRNA-DOPC or 2B-siRNA-DOPC ( Figure 4B and 4D) .
Effect of survivin silencing on angiogenesis, cell proliferation, and apoptosis
Since silencing of T-survivin induced cell growth inhibition and apoptosis in vitro and silencing of survivin 2B resulted in cell cycle arrest with few apoptotic events, we examined the effects of the siRNA-DOPC therapy on cell proliferation, apoptosis and microvessel density (MVD) in tumors dissected from the previous experiment. T-siRNA-DOPC and 2B-siRNA-DOPC treatment resulted in decreased MVD when compared to controls (Fig 5A) , which was further decreased by combination treatment with docetaxel. Cell proliferation was assessed by staining for the nuclear marker Ki-67. T-siRNA-DOPC and 2B-siRNA-DOPC induced a significant (T-siRNA-DOPC (***p<0.001, and 2B-siRNA-DOPC **p<0.01) reduction in the Ki-67 index. TUNEL data analysis ( Figure 5C ) showed a significant induction of apoptosis in mice treated with T-siRNA-DOPC alone (*p<0.05), 2B-siRNA-DOPC alone (**p<0.01) or in combination with DTX (T-siRNA-DOPC (***p<0.001, and 2B-siRNA-DOPC **p<0.01). However higher apoptotic events were observed in T-siRNA-DOPC plus docetaxel group compared with 2B-siRNA-DOPC plus docetaxel group.
Survivin-2B expression in human ovarian carcinoma
Survivin and its splice variants are over-expressed in most cancers (14, 38) including ovarian cancer (11, 39) . However most of these studies were performed by RT-PCR or immunohistochemistry (with an antibody against all survivin splice variants) and do not represent truly quantitative measures. The expression of survivin 2B is ovarian cancer has not been studied. Thus, we examined the messenger RNA expression levels of survivin 2B in 117 epithelial ovarian cancers obtained at primary debulking surgery by real-time PCR. Two-fold difference between the mRNA abundance for each sample and the mRNA control (normal ovarian epithelial cells) was considered as survivin 2B overexpression (27, 28, 40) . Out of the 117 specimens, 24% (n=28) showed high levels of survivin 2B mRNA (Table S1 ). We found that survivin 2B overexpression was significantly (p<0.005) associated with progression free survival (PFS; Figure. 6A), and with overall survival (OS, p<0.009; Figure 6B ). The relation between clinicopathological variables (stage, histology, grade, ascites and cytoreduction) and survivin-2B mRNA expression was also examined (Table 1S) . Survivin-2B mRNA was significantly (p<0.07) higher in high stage tumors versus low stage disease. We also examined the effect of survivin-2B expression on patient survival in multivariable analysis. This analysis revealed that high survivin-2B expression (p=0.02) remained statistically significantly associated with patient survival after controlling for primary cytoreductive surgery, tumor stage and grade, histology, and patient age.
Discussion
The key finding from our study is that siRNA-based silencing of the survivin splice variant 2B inhibits cell growth in vitro and reduces tumor growth in orthotopic models of taxane-resistant ovarian cancer. Furthermore, survivin-2B mRNA was detected in a substantial proportion of ovarian cancers, and was associated with poor of PFS and OS in ovarian cancer patients.
Several reports have shown the role of survivin in drug resistance of ovarian cancer cells (11, 39, Research.
on July 14, 2017. © 2011 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 41 ). However, the role of survivin-2B in taxane-resistant ovarian cancer cells had not been addressed. Our finding that survivin-2B is more abundant in taxane-resistant than in taxanesensitive ovarian cancer cells, confirm previous results that each survivin splice variant could have specific intracellular roles as anti-apoptotic or cell cycle regulator proteins (14, 15, 17, 42) .
SiRNA-based silencing of survivin-2B induced similar growth inhibitory effects than silencing of all survivin splice variants at the same time, demonstrating that this survivin 2B could have a central role in cell growth, viability, and drug resistance of ovarian cancer cells. The cell cycle arrest in G1 upon survivin 2B silencing suggests that the main intracellular role of this isoform may be related to the regulation of cell cycle rather than apoptosis. In addition, our in vivo data confirmed that survivin 2B silencing induced lower apoptosis than silencing all survivin splice variants at the same time. This hypothesis is supported by the fact that survivin 2B is the only isoform that retains the C-terminal coiled coil domain necessary to the interaction with INCEP for the CPC formation during mitosis (14) .
Earlier reports indicated that survivin 2B could have lost its anti-apoptotic function (15, 16, 19, 21) or even have a pro-apoptotic role (22) . More recent survivin overexpression studies in human epithelial carcinoma A431 cell line performed by Knauer et al showed that survivin-3B was the only survivin isoform able to protected clones against cisplatin-induced apoptosis (18) . Our data showed that silencing of survivin 2B in taxane-resistant ovarian cancer cells induced cell growth arrest in vitro and in vivo. In fact, the additional siRNA against survivin 2B that we used here was the one used by Ling et al (22) in which they observed an increase in cell resistance to paclitaxel- mediated growth inhibition of MCF-7 cells. Although our experiments were performed in different cell lines than those reported by others (16, 21, 22) , our observation that siRNA-based silencing survivin 2B induced cell cycle arrest with minor apoptotic events (in vitro and in vivo) are more in agreement with a role of survivin 2B in the control of cell cycle progression (14) . Survivin 2B silencing could lead to a mitotic catastrophe as previously observed after survivin deletion in vitro and in vivo, with survivin dominant-negative mutants (5, 8, 43, 44) . The increasing levels of p27 and the decreased levels of cyclin-E and cdk2 with the concomitant arrest in G1 of survivin 2B-depleted HEYA8.MDR cells observed in our study correlates with the role of survivin 2B in the mitotic progression.
There is evidence suggesting that survivin induces drug resistance by stabilizing tubulin polymers The mRNA expression of survivin 2B has been assessed in different cancers (14, (46) (47) (48) .
However contrasting results were obtained regarding the correlation between survivin 2B expression levels and clinicopathological markers (14, (46) (47) (48) (49) 
mainly due to the use of non-specific primers to amplify specifically survivin 2B, or the use of semi-quantitative analysis of gel images obtained by RT-PCR (14, 49) . This is the first report showing mRNA survivin 2B expression levels in ovarian cancer patients. The strong difference in the OS between ovarian cancer patients with high vs. low survivin 2B suggest that this splice variant could be used as a prognostic markers for ovarian cancer.
Although survivin is highly abundant in most cancers, growing evidence indicate that survivin could regulate the proliferation and survival of normal adult cells (50) , especially those with continual renewal. On the basis of our results that silencing survivin 2B induces similar growth inhibition in vitro and in vivo than inhibiting all survivin splice variants at the same time, we propose the use of survivin 2B-siRNA-DOPC as a novel and specific anti-survivin therapy without compromising all intracellular pools of survivin in normal adult tissues. 
